Summary: Atomic force microscopy (AFM) provides a new technology to visualize the cellular topography and quantify the molecular interactions at nanometer spatial resolution. In this work, AFM was used to image the cellular topography and measure the molecular force of pathological cells from B-cell lymphoma patients. After the fluorescence staining, cancer cells were recognized by their special morphological features and then the detailed topography was visualized by AFM imaging. The AFM images showed that cancer cells were much rougher than healthy cells. CD20 is a surface marker of B cells and rituximab is a monoclonal antibody against CD20. To measure the CD20-rituximab interaction forces, the polyethylene glycol (PEG) linker was used to link rituximab onto the AFM tip and the verification experiments of the functionalized probe indicated that rituximab molecules were successfully linked onto the AFM tip. The CD20-rituximab interaction forces were measured on about 20 pathological cells and the force measurement results indicated the CD20-rituximab binding forces were mainly in the range of 110-120 pN and 130-140 pN. These results can improve our understanding of the topography and molecular force of lymphoma pathological cells. SCANNING 00: 1-7, 2012. C 2012 Wiley Periodicals, Inc.
Introduction
With the advancement of research methods in biochemistry, the intracellular chemical processes have been gradually clarified. However, the traditional bulk biochemical experiments in test tubes may not reflect the complete processes in vivo owing to their inherent ensemble averaging (Cecconi et al., 2005) . The test tube measurements provide averaged information obtained on large ensembles of molecules from many cells (Dufrene, 2009) . Undoubtedly, the results deduced from the ensemble measurements are correct for depicting the behavior of the ensemble molecules, but on the other hand, the ensemble measurements hide the rare events and the variable properties of individual molecules (Dupres et al., 2009) . As opposed to test tube experiments, single-molecule techniques allow one to look beyond ensemble averages (Zhuang et al., 2000) and thereby can reveal the events and properties that would otherwise be inaccessible, providing new insights for understanding the cellular physiological activities at individual cell/molecule levels. Consequently, utilizing singlemolecule techniques to investigate the behavior of individual cells/molecules has become a new research hotspot in life sciences (Kodera et al., 2010; Katan and Dekker, 2011) .
One of the most common single-molecule techniques is atomic force microscopy (AFM) (Binnig et al., '86) , which is widely used in life sciences since its invention. The main advantage of AFM is that it can directly image the topography of biological samples at nanometer resolution under physiological conditions, without the need of labeling, staining, or fixation. Besides imaging, AFM is also a force probe tool with picoNewton force sensitivity. This makes it suitable to measure the binding forces of individual receptor-ligand pairs and this technology is called single-molecule force spectroscopy (SMFS) (Muller et al., 2009) . In SMFS, ligands (or receptors) are attached to the AFM cantilever tip and the cognate receptors (or ligands) are tethered to a support. SMFS can also be applied to directly measure the specific binding forces of receptors on cell surface (Puntheeranurak et al., 2006; Lee et al., 2007; Shi et al., 2009) . Up to now nearly all SMFS experiments were performed on isolated biomolecules (Dufrene et al., 2011) or on cells cultured in vitro (Puntheeranurak et al., 2006; Lee et al., 2007; Shi et al., 2009) . Biomolecules in vivo are highly controlled by their environments (Dufrene et al., 2011) and hence the isolated proteins may alter their properties. Cells grown on flat two-dimensional cell culture can differ considerably in their morphology and character from those growing in tissues and organs (Yamada and Cukierman, 2007) . Thus, the cells cultured in vitro may not reproduce all the facets of human responses to diseases. Consequently, investigating the behaviors of cells from patients will have a significant impact. In this work, we used AFM to image the cellular topography and measure the molecular force directly on pathological cells from lymphoma patients.
Material and Methods

Sample Preparation
The pathological cells were prepared from the bone marrow of B-cell lymphoma patients whose bone marrow was intruded by lymphoma cells. Poly-Llysine was used to immobilize cells onto the glass slide. Drop poly-L-lysine solution onto the fresh glass slides and store at room temperature for natural drying. A paracentesis needle was used to acquire the bone marrow from the lymphoma patients. Then, the bone marrow was dropped onto the poly-L-lysinecoated glass slides and another glass slide was used to disperse the bone marrow and 4% formaldehyde was used for fixation.
Probe Functionalization
The heterobifunctional linker molecule NHS-PEG2000-MAL (JenKem Company, China) was used to link rituximab onto the AFM tip. The probe functionalization procedure followed an established procedure (Stroh et al., 2004) . The NHS end of the PEG linker reacts with amines on the silicon tip, yielding a stable amide bond, while the MAL group reacts with a protein thiol resulting in a disulfide linkage between PEG and protein (Ebner et al., 2007) .
Scanning Electron microscopy (SEM) and Fluorescence Microscopy
SEM and fluorescence microscopy were applied to verify that rituximab had been linked onto AFM tips. For SEM, the functionalized probe was attached onto a copper puck. Then place the puck onto the stage of the SEM for being scanned. For control experiments, the normal probe was scanned by SEM as same as the functionalized probe. For fluorescence validation, the Rhodamine B isothiocyanate (RBITC) labeled goat anti-human IgG was used. First, the functionalized probe was placed into a petri dish in PBS and then the IgG solution was added and incubated for 1 h. After the reaction, the probe was rinsed with PBS to remove the unbound IgG and then was placed onto the stage of the fluorescence microscope. For control experiments, the normal probe was treated as same as the functionalized probe.
For cancer cell recognition, rituximab and RBITClabeled goat anti-human IgG were used. (1) Put the slide pathological cell sample into a petri dish with 10 mL PBS. Add 1mL rituximab into the petri dish and incubate in 4
• C for 4 h. 
AFM Imaging and Force Measurements
AFM imaging and measurements were performed using a Bioscope Catalyst AFM (Veeco Company, Santa Barbara, CA) with silicon nitride probes. The nominal spring constant of the cantilever used was 0.06 N/m. The spring constant was calibrated by a Thermal Tune Adapter (Veeco Company, Santa Barbara, CA). The normal probes were used to image the topography of cancer cells from lymphoma patients at room temperature in air under the guidance of fluorescence. The imaging mode was contact mode. The SMFS experiments were performed on pathological cells at room temperature in PBS. The functionalized probes were moved onto the patient cells guided by the optical system and force curves were obtained on the cell surface. About 1,000 force curves were obtained for each pathological cell. Figure 1 shows the fluorescence staining images of cells from lymphoma patients. The optical images of the pathologic bone marrow sample from lymphoma patients are provided in Figure 1A and D. The corresponding fluorescence images are provided in Figure 1B and E. We can see that most of the cells of the pathologic sample did not exhibit red fluorescence. We know that CD20 is only expressed on B lymphocytes (B cells). While in the bone marrow, cells (such as red blood cells) that do not express CD20 are in the majority. Hence, we saw only a few cells were stained with red fluorescence. For these cells that exhibited fluorescence, a proportion of them had prominent features, such as round nucleus with central nucleolus (Bouabdallah et al., 2003) (Fig. 1C) , or irregular nucleus with splitting nucleolus and these indicated that these cells were cancer cells (Fig. 1F) . We can see that cancer cells were the minority of the pathologic cell sample and the cancer cells had special morphological features on nucleus.
Results
Cancer Cell Recognition and AFM Imaging
Guided by the fluorescence, the detailed topography of cancer cells was imaged by AFM, as shown in Figure 2 . From the fluorescence image ( Fig. 2A, E) , we can see a cancer cell (denoted by the circles). Then, the AFM probe was moved to the cancer cells. First, a large scan (100 μm) was performed, and the topography image (Fig. 2B, F ) was obtained. The cancer cell can easily be recognized in the AFM images (denoted by the square in Fig. 2B, F) . By zooming into a small area (30 μm), the higher topography images of the cancer cell were observed (Fig. 2C, D , G and H) . From the AFM images of the cancer cells, we can see that comparing with the healthy cells on the sample, cancer cells exhibit different morphology. The healthy cells have smooth and plump surfaces, while the cancer cells have corrugated and hollow surfaces. By applying AFM processing software, the roughness of the cell surface was computed. Figure 3A was the roughness curve of a local area (4 μm) on the cancer cell surface (denoted by the square). Figure 3B was the roughness curve on the healthy cell surface (denoted by the square). The roughness of the cancer cell was 78.34 nm, while the roughness of the healthy cell was 21.31 nm. To quantitatively measure the cellular roughness, eight cancer cells and eight healthy cells were chosen to compute the roughness and the contrast of roughness of cancer cells and healthy cells was shown in Figure 3C . We can see that cancer cells were about four times rougher than healthy cells.
Probe Functionalization
To measure the CD20-rituximab binding forces, PEG molecules were used to link rituximabs onto the AFM tip. After the functionalization procedure, we should check whether rituximab molecules had been linked onto the tip. Figure 4 shows the SEM and fluorescence microscopy results of verification experiments. The SEM images of a normal tip and the SEM images of a functionalized tip are provided in Figure 4A and B and Figure 4C and D, respectively. We can see that there were many particles on the surface of the functionalized tip (denoted by the arrows in Fig. 4D ) while the surface of the normal tip was smooth. The optical images were shown in Figure 4E and G and the corresponding fluorescence images were shown in Figure 4F and H, respectively. We can see that the fluorescence of functionalized tip was bright and the fluorescence around the tip (denoted by white circle in Fig. 4H ) was obviously brighter than other areas, while the fluorescence of the normal tip was dim. The tip shape was pyramidal and the tip height was in the range of 2.5-8.0 μm. After the functionalization procedure, rituximabs bound onto the tip surface through PEG linker. Rituximabs should also bind onto the cantilever of the probe. But the density of rituximabs on the tip was much larger than in the cantilever. Then, after the fluorescence staining, the density of fluorescein-labeled secondary antibody on the tip was much more than on the cantilever and this resulted in that the fluorescence of the tip was markedly brighter than that of the cantilever. Hence, through the functionalization procedure, rituximab molecules were successfully linked onto the AFM tip. 
Molecular Force Measurements on Pathological Cells
The CD20-rituximab binding forces were measured quantitatively on pathologic cells by using the functionalized tips. The method used here was using the functionalized tips to obtain force curves on cells from the sample. If the force curves had prominent abrupt peaks, then the cell was chosen for measuring the CD20-rituximab binding forces. Figure 5A was a typical force curve where the abrupt peak indicated the CD20-rituximab specific binding. The inset in Figure 5A was the principle of the force measurement. Rituximabs were linked onto the AFM tip and then the tip was approached and contacted with the CD20 molecules on the cell surface, obtaining force curves during the approach-retract process. CD20 is a four-transmembrane B cell-specific molecule that functions as a membrane-embedded Ca 2+ channel (Lebien and Tedder, 2008) . The binding of rituximab to CD20s on the B-cell surface can result in the depletion of the B cell by three mechanisms, including FcFcrR interactions, complement-dependent cytotoxicity (CDC), and the programmed cell death (PCD) (Alduaij and Illidge, 2011) . For each cell, ∼1,000 force curves were obtained at the same loading rate 1.99 μm/s. For these 1,000 force curves, only a small proportion of them had typical molecular recognition abrupt peaks and these curves were selected to compute the binding force. Figure 5B was a typical force curve when no CD20-rituximab binding occurred. We can see that there was also a peak in Figure 5B and this is because of the nonspecific adhesion interactions between tip and cell surface. The magnitude of the peak in Figure 5B was very small and the shape of the peak indicated they were nonspecific adhesion force. For contrast, we can see that the peak in Figure 5A had a step-like shape (indicated by the arrow) and this shape was caused by the stretching of PEG linker and this shape was the typical fashion of molecular binding (Hinderdorfer et al., '96) . Figure 5C was the histogram of the binding forces of one cell and the Gaussian fit indicated that the binding force was 132 ± 51 pN. The binding forces of the 22 different cells were shown in Figure 5D . We can see that the binding forces were mainly in the range of 
Discussion
A century ago, Paul Ehrlich envisioned antibodies as "magic bullet" that would specifically trace and kill tumor cells (Schrama et al., 2006) . His dream is now not only a reality but a major aspect of clinical medicine (Schwartz, 2004) : more than 25 antibodies are approved for human therapy and more than 240 antibodies are currently in clinical development worldwide (Chan and Carter, 2010) . The prosperity of antibody engineering was largely because of the unprecedented success of rituximab in the treatment of B-cell lymphomas since its approval in 1997. Rituximab is a powerful drug against B-cell lymphoma, but many patients with CD20-positive malignancies still fail to respond to the rituximab-containing immunochemotherapy (Alduaij and Illidge, 2011) . The underlying mechanisms for the rituximab resistance remain unknown (Taylor and Lindorfer, 2010) and this problem has become a big challenge for the pharmaceutical industry to develop the next generation of antibody-targeted drugs. The advent of AFM, especially the rapid development of high-speed AFM in recent years (Kodera et al., 2010) , opens an opportunity to understand the rituximab resistance at individual cell/molecule levels under physiological conditions and may provide novel insights into the cellular processes. Since the current researches of AFM were mainly on cells cultured in vitro, using AFM to investigate the behavior of pathological cells may have a significant impact.
Since its invention, AFM has been used for cell imaging (Butt et al., '90) . AFM provides higher spatial resolution than optical microscopy and can even image single molecule on the membrane (Casuso et al., 2011) . With AFM imaging, the topography changes of single living cells can be observed (Rotsch and Radmacher, 2000) . Currently, most of the AFM studies were performed on cells cultured in vitro. Investigating the topography of pathological cells from patients has, to our knowledge, not been largely reported before. Researchers have imaged the pathological erythrocytes from a patient with hereditary spherocytosis and observed the changes of the cell shape (Dulinksa et al., 2006) . Also, the mechanical properties of metastatic cancer cells and benign cells from cancer patients have been investigated by AFM (Cross et al., 2007) . Here, under the guidance of fluorescence, the detailed topography of lymphoma cancer cells were imaged by AFM and the AFM images showed that cancer cells were corrugated while the healthy cells were smooth, as shown in Figure 2 . Besides, the roughness of the cancer cells and healthy cells was quantitatively measured. We chose eight cancer cells and eight healthy cells to compare their roughness. The roughness measurement results indicated that cancer cells were about four times rougher than healthy cells (Fig. 3) . We know that the genetic alterations drive the progressive transformation of normal human cells into malignant cells (Hanahan and Weinberg, 2000) . These genetic alterations may cause the cellular changes, such as the elasticity and the roughness. Researchers have indicated that cancer cells were softer than normal cells (Cross et al., 2007) . Here, we can see that cancer cells were rougher than normal cells.
With SMFS, many types of molecular binding forces had been measured before. The binding force of single biotin-avidin was about 160 pN (Florin et al., '94) , and the binding force of single antibody-antigen (human serum albumin and antibody) was about 244 pN (Hinterdorfer et al., '96) . These two measurements were performed on isolated proteins. The experiments on living CHO cell surface indicated that the binding force of single antibody-antigen (SGLT1 and antibody) was about 100 pN (Puntheeranurak et al., 2006) . Usually the binding force of single receptorligand interactions are about 20-200 pN (Muller et al., 2009) . Here, we measured the binding forces of CD20-rituximab on 22 pathological cells. The results indicated that the binding forces were mainly in the range of 110-120 pN, 130-140 pN. Hence, the forces measured here were in the normal range of single receptor-ligand binding force. We know that for the lymphoma patients whose bone marrow was intruded by lymphoma cells, there are normal B cells and malignant B cells in the bone marrow. These 22 cells measured here may include both normal B cells and malignant B cells. Malignant B cells were quite different from normal B cells (Klein and Dalla-Favera, 2008; Kotani et al., 2010) and this difference may cause different properties of the malignant cells and normal cells, such as antibody-antigen affinity. Researchers have indicated that the distribution of CD20 and cellular surface ultrastructre of normal B cells were quite different than that of B-chronic lymphocytic leukemia cells (Wang et al., 2011) . Besides, B cells have many different types, including pro-B cells, pre-B cells, mature B cells, memory B cells, and plasma B cells (Lebien and Tedder, 2008) . These different B cells may also have different surface structures that may induce different antibodyantigen affinities. Compared to the CD20-rituximab binding force (about 80 pN) on lymphoma Raji cells cultured in vitro (Li et al., 2010) , we can see that the binding forces on pathological cells were much larger than that on Raji cells. This may be because of the different environments of pathological cells and Raji cells. Pathological cells were in vivo, while Raji cells were cultured in vitro. This difference may cause the different CD20-rituximab binding forces.
In summary, the rapid developments in AFM single-molecule techniques have allowed researchers to characterize the behavior and measure the binding forces of single molecules. Here, we used AFM to investigate the cellular morphology and molecular force directly on lymphoma pathological cells. The AFM images showed the special topography (corrugated, hollow) of cancer cells compared to healthy cells (smooth, plump) and the roughness measurements indicated that cancer cells were about four times rougher than healthy cells. The molecular force measurements indicated that the CD20-rituximab binding forces of pathological cells were mainly in the range of 110-120 pN, 130-140 pN, significantly larger than that on Raji cells. These results will facilitate further researches of rituximab's different efficacies.
